Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000440915 | SCV000531207 | uncertain significance | not provided | 2024-09-07 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV001230161 | SCV001402633 | likely benign | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5 | 2024-09-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002522473 | SCV003723320 | uncertain significance | Inborn genetic diseases | 2021-06-11 | criteria provided, single submitter | clinical testing | The c.5105G>A (p.R1702Q) alteration is located in exon 41 (coding exon 41) of the CACNA1S gene. This alteration results from a G to A substitution at nucleotide position 5105, causing the arginine (R) at amino acid position 1702 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005004157 | SCV005629398 | uncertain significance | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5; Thyrotoxic periodic paralysis, susceptibility to, 1; Congenital myopathy 18 | 2024-03-21 | criteria provided, single submitter | clinical testing |